BeOne Medicines (BEIGF) Gains from Investment Securities (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Gains from Investment Securities data on file, last reported at $4.7 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $4.7 million, down 49.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 million (up 67.01% YoY), and the FY2025 annual result was $1.2 million, changed N/A from the prior year.
• Gains from Investment Securities climbed to $4.7 million in Q1 2026 per BEIGF's latest filing, from -$78.7 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $69.8 million in Q3 2025 and troughed at -$78.7 million in Q4 2025.
• A 5-year average of $561470.6 and a median of $4.0 million in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities jumped 5327.02% in 2023, then sank 590.02% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$23.5 million in 2022, then tumbled by 71.94% to -$40.4 million in 2023, then increased by 27.25% to -$29.4 million in 2024, then tumbled by 167.58% to -$78.7 million in 2025, then soared by 106.03% to $4.7 million in 2026.
• Business Quant data shows BEIGF's Gains from Investment Securities at $4.7 million in Q1 2026, -$78.7 million in Q4 2025, and $69.8 million in Q3 2025.